MassIVEapplication/xmlftp://massive-ftp.ucsd.edu/v03/MSV000085363/primaryOK2001000David Gonzalezhttps://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=1466da429dc8497ab3772331db4852a2djgonzalez@ucsd.eduMassIVE30UNIMOD:4 - "Iodoacetamide derivative."UNIMOD:737 - "Sixplex Tandem Mass Tag."UNIMOD:35 - "Oxidation or Hydroxylation."ProteomicsOrbitrap FusionMycobacterium Abscessus Atcc 19977 (ncbitaxon:561007)UCSD<i>Mycobacterium abscessus</i> subsp. <i>abscessus</i> (MAB) is a clinically important nontuberculous mycobacterium (NTM) causing pulmonary infection in patients such as cystic fibrosis and bronchiectasis. MAB is naturally resistant to the majority of available antibiotics. In attempts to identify the fundamental response of MAB to aerobic, anaerobic, and biofilm conditions (as it is encountered in patients) and during exposure to antibiotics, we studied bacterial proteome using tandem mass tag mass spectrometry sequencing. Numerous de novo synthesized proteins belonging to diverse metabolic pathways were found in anaerobic and biofilm conditions, including glycolysis/gluconeogenesis, tricarboxylic acid (TCA) cycle, oxidative phosphorylation, nitrogen metabolism, and glyoxylate and dicarboxylate metabolism. Upon exposure to amikacin and linezolid under stress environments, MAB displayed metabolic enrichment for glycerophospholipid metabolism and oxidative phosphorylation. By comparing proteomes of two significant NTMs, MAB and <i>M. avium</i> subsp. <i>hominissuis</i>, we found highly synthesized shared enzymes of oxidative phosphorylation, TCA cycle, glycolysis/gluconeogenesis, glyoxylate/dicarboxylate, nitrogen metabolism, peptidoglycan biosynthesis, and glycerophospholipid/glycerolipid metabolism. The activation of peptidoglycan and fatty acid biosynthesis pathways indicates the attempt of bacteria to modify the cell wall, influencing the susceptibility to antibiotics. This study establishes global changes in the synthesis of enzymes promoting the metabolic shift and enhancing the pathogen resistance to antibiotics within different environments.Exposure of <i>Mycobacterium abscessus</i> to Environmental Stress and Clinically Used Antibiotics Reveals Common Proteome Response among Pathogenic Mycobacteria.Rojony Rajoana R, Danelishvili Lia L, Campeau Anaamika A, Wozniak Jacob M JM, Gonzalez David J DJ, Bermudez Luiz E LEantibiotic, antimicrobial, Antimycobacterial Agents, Anti Bacterial Agents, antibiotique, determination, Antibacterial, antimicrobials, Compounds, Antibiotika, Anti Bacterial Compounds, Anti Bacterial Compound, chemical analysis., antimicrobial agents, Antibacterial Agent, Anti-Mycobacterial, Anti-Bacterial Compounds, Bacteriocidal Agent, Antibacterial Agents, Anti Mycobacterial Agents, Agent, Anti-Bacterial Agent, Anti-Bacterial, microbicides, Agents, Anti-Mycobacterial Agents, Compound, Anti Mycobacterial Agent, Antimycobacterial Agent, Antibiotic, microbicide, Bacteriocidal, Antibiotics, assay, Anti-Bacterial Compound, Bacteriocidal Agents, Bacteriocide, Anti Bacterial Agent, Bacteriocides, Anti-Mycobacterial Agent, Antimycobacterial, antibiotics, Antibiotikumnumber, total expressed protein, count in organism, methods, experimental procedures., experimental, Proteomes, presence, experimental sectionantibiotic, Mycobacterium abscessus subsp. abscessus, antibiotique, Mycobacterium abscessus subsp. bolletii, antimicrobials, Compounds, Mycobacterium chelonae abscessus, total expressed protein, antimicrobial agents, "Mycobacterium chelonei" (sic) Bergey et al. 1923, Antibacterial Agent, Anti Mycobacterial Agents, Agent, microbicides, Anti Mycobacterial Agent, responsivity, Mycobacterium abscessus, Mycobacterium chelonei subsp. abscessus, Antibiotic, microbicide, Bacteriocidal, EnvironmentalStress, Bacteriocidal Agents, Bacteriocide, Anti Bacterial Agent, Bacteriocides, Anti-Mycobacterial Agent, Antimycobacterial, antibiotics, Mycobacteroides abscessus subsp. massiliense, Mycobacterium chelonae subsp. abscessus, Mycobacterium abscessus subspecies abscessus, antimicrobial, environmental stress, reactivity, Antimycobacterial Agents, Anti Bacterial Agents, Antibacterial, Mycobacteria., Antibiotika, Anti Bacterial Compounds, Anti Bacterial Compound, common, Mycobacterium abscessus bolletii, Anti-Mycobacterial, Anti-Bacterial Compounds, Bacteriocidal Agent, Antibacterial Agents, Anti-Bacterial Agent, Anti-Bacterial, Mycobacteroides abscessus, Agents, Anti-Mycobacterial Agents, Compound, Mycobacterium massiliense, Mycobacterium abscessus Complex, Mycobacteroides abscessus subsp. abscessus, Antimycobacterial Agent, Mycobacterium abscessus subspecies bolletii, Antibiotics, response, Anti-Bacterial Compound, Mycobacterium bolletii, "Mycobacterium abcessus" Moore and Frerichs 1953, Proteomes, Mycobacterium abscessus abscessus, Antibiotikumsodium salt, Metabolic Networks, glucose biosynthetic process, Amikacina, antimicrobials, Compounds, Zyvox, HNT, fond, l(3)72Da, Meconium obstruction of intestine in mucoviscidosis, Metabolic Concepts, antimicrobial agents, Embden-Meyerhof, A.M.K, CycEI, IGLON2, Amikacina Medical, microbicides, Oxidative, Anti Mycobacterial Agent, responsivity, Mycobacterium abscessus, hnt, dicarboxylate metabolic process, Analysis, Metabolism Concept, Bacteriocide, modifier of, WMS, Mycobacteroides abscessus subsp. massiliense, Mycobacterium abscessus subspecies abscessus, antimicrobial, Analyses, catabolism, anabolism, Antibiotika, N, Anti Bacterial Compound, Pathways, U, metabolic process resulting in cell growth, cystic fibrosis with gastrointestinal manifestations, Varicose, Bacteria Woese et al. 2024, CF, Amikayect, Bacteria <bacteria>, Bronchiectasis, Prokaryotae, Mycobacteroides abscessus subsp. abscessus, Antimycobacterial Agent, 2-(14)C-labeled, Infections and Infestations, Procaryotae, SGS, Pathway, DmelCG13076, Krebs cycle, metabolism resulting in cell growth, fatty acid anabolism, anaerobic glycolysis, dicarboxylate, "Mycobacterium chelonei" (sic) Bergey et al. 1923, Embden-Meyerhof-Parnas, Cyc E, Cylindrical, Spectrum Analysis, ACMICD, Embden-Meyerhof-Parnas Pathway, Amikacin Sulfate, BG:DS07108.3, Stickstoff, CYSTIC FIBROS W/O ILEUS, peptidoglycan formation, secretion, prokaryotes, PNU100766, Pancreatic, Anti Bacterial Agent, l(2)05206, Bacteriocides, Anti-Mycobacterial Agent, activation, Antimycobacterial, Acid, Phosphorylation, Pancreatic Cystic Fibrosis, Antibacterial, Spectrometry, Infection and Infestation, Bronchiectases, oxoethanoic acid, Fibrocystic Disease of Pancreas, nitrogen, glycolysis, glyoxylate, Mycobacterium Lehmann and Neumann 1896 (Approved Lists 1980), U100766, Mycobacterium abscessus subspecies bolletii, Acids, Embden-Meyerhof Pathways, cystic fibrosis with pulmonary manifestations (disorder), Prokaryota, dicarboxylic acid dianion, Amikason's, cycline, Mycobacterium abscessus subsp. abscessus, antibiotique, Processes, Biocatalysts, DmcyclinE, Amikin, Mycobacterium chelonae abscessus, biosynthesis, l(3)72CDf, Metabolic Processes, Agent, cdi7, cyclinE, a dicarboxylate, Gene Products, Cdi7, CDI7, Antibiotic, Polynesian bronchiectasis, cystic fibrosis lung disease, Medical, Meconium ileus in cystic fibrosis (disorder), Pulmonary, Cystic Fibrosis of Pancreas, cystic fibrosis with other manifestations, N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide, Metabolic Concept, cystic fibrosis with combined manifestations, DmcycE, clinical infection, peptidoglycan synthesis, synthesis, Bacteria (ex Cavalier-Smith 1987), Cystic Fibrosis, Anti-Bacterial, Enzyme, Oxidative Phosphorylations, Pseudomurein, Amikacina Normon, Antibiotics, Linezolide, dicarboxylic acid dianions, Antibiotikum, pseudomonas aeruginosa, bacteria, degradation, Proteins, Gamikal, Phosphorylations, BBK8, BB K 8, Phosphoglycerides, murein sacculus, Permanent enlargement of the airways of the lungs, Cell, alpha-glycerophosphate pathway, Concept, cystic fibrosis with pulmonary manifestations, glyoxylic acid, MS, Amukin, l(2)k02514, DmCycE, amikacine, peptidoglycan, MFS1, amikacina, Biklin, Bacteriocidal Agents, metabolism, Mass Spectrum Analyses, Metabolic Pathways, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine, anon-WO03062410.10, Metabolic Phenomenon, covalent modifier, Wall, susceptibility, multicellular organism metabolic process, l(2)k02602, Normon, azote, Bacteriocidal Agent, Anti-Bacterial Agent, Cystic, Gene Proteins, D-CycE, Glyoxylate, Nt, oxalaldehydic acid, Compound, prokaryote, "Mycobacterium abcessus" Moore and Frerichs 1953, Sulfate, Anabolism, biochemical pathways, Cystic fibrosis NOS, Networks, Varicose Bronchiectasis, Metabolic Process, dicarboxylic acid metabolism, susceptibility to chronic infection by, Infestations and Infections, Glycerophospholipid, formylformic acid, glycerolipid metabolism, Embden Meyerhof Parnas Pathway, Cylindrical Bronchiectases, Ccne, Concepts, envelope, Embden-Meyerhof Pathway, Phenomenon, BB-K8, dicarboxylates, multicellular organismal biosynthetic process, Mass Spectrum Analysis, Cell Walls, Antimycobacterial Agents, single-organism biosynthetic process, Eubacteria, enzymes, murein biosynthetic process, NTRI, Mycobacterium abscessus bolletii, Anti-Bacterial Compounds, Fibrocystic disease, Cystic Bronchiectasis, Murein, biotransformation, Pulmonary Cystic Fibrosis, Mycobacterium bolletii, Varicose Bronchiectases, GPHYSD2, Catabolism, PNU-100766, antibiotic, Saccular, Process, U-100766, Mycobacterium abscessus subsp. bolletii, Mucoviscidosis, peptidoglycan biosynthesis, Cystic fibrosis NOS (disorder), O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, Metabolic Network, Antibacterial Agent, br37, fatty acid formation, Glyoxalsaeure, CF - Cystic fibrosis, Spectroscopy, Glyoxylsaeure, Antibiotikum., alpha-ketoacetic acid, BBK 8, Biclin, Mycobacterium chelonei subsp. abscessus, Not, microbicide, Phosphoglyceride, Fibrosis, glyoxalic acid, Biofilm, peptidoglycan anabolism, Cylindrical Bronchiectasis, in cystic fibrosis, BB-K 8, Cystic fibrosis (disorder), Kanbine, wf, cystic fibrosis, MASS, amikacinum, murein biosynthesis, Embden-Meyerhof pathway, Antibacterial Agents, l35Dd, Agents, notum, Patient, mucoviscidosis, Tricarboxylic Acid, BB K8, Pancreas Fibrocystic Disease, Biocatalyst, Mycobacterium abscessus Complex, Amikalem, fatty acid biosynthesis, 7N, Oprad, Proteomes, Mycobacterium abscessus abscessus, Amiklin, FBN, Gene, Pancreas Fibrocystic Diseases, cycE, Network, eubacteria, Spectrum Analyses, l(2)br37, CYCLE, Mycobacteria, ECTOL1, Metabolism, 14C-labeled, modified Embden-Meyerhof pathway, Mass, cystic fibrosis with other manifestations (disorder), U 100766, citric acid cycle, Bacteriocidal, Saccular Bronchiectases, Bacteriobiota, Metabolism Phenomena, antibiotics, Mass Spectroscopy, Walls, Mycobacterium chelonae subsp. abscessus, reactivity, study, Amikacin, CYCE, cystic fibrosis with meconium ileus, D-Streptamine, formation, DmelCG3938, CyclE, Anti Bacterial Compounds, 3938, anon-WO0118547.482, respiratory-chain phosphorylation, Anti-Mycobacterial, Monera, OCTD, l(2)k05007, Infestation and Infection, dm-cycE, Glyoxalate, ntm, 1-N-(L(-)-gamma-amino-alpha-hydroxybutyryl)kanamycin A, Mycobacteroides abscessus, Anti-Mycobacterial Agents, Clients, dicarboxylate metabolism, fatty acid synthesis, fungi, TAG, PNU 100766, Amikafur, amikacin, Embden Meyerhof Pathway, synthesize, total expressed protein, enzyme activity, Client, (S)-, Anti Mycobacterial Agents, Metabolic Phenomena, Metabolism Concepts, 14C2-labeled, oxidative TCA cycle, Protein, Phenomena, Infection, CyeE, Saccular Bronchiectasis, WMS2, Mass Spectrum, Anti Bacterial Agents, anon-WO03062410.8, biodegradation, Metabolic, Tricarboxylic, l(2)35Dd, Cystic fibrosis without mention of meconium ileus, glucose biosynthesis, cystic fibrosis with meconium ileus (disorder), Embden-Meyerhof-Parnas pathway, nitrogeno, Protein Gene Products, TCA cycle, SSKS, Mycobacterium massiliense, calcium salt, Metabolic Pathway, Cystic Bronchiectases, response, Anti-Bacterial Compound, CG13076, CG3938, Yectamid, 1007661PXD018957falseMabscessus_Antibiotics_Proteomic_AnalysisQuantitative proteome of M. Abscessus in various experimental conditions.Sun May 03 10:33:00 BST 2020MSV00008536332397563